Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 3Brain Neoplasms 2Oligodendroglioma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Castrate-resistant Metastatic Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 3Magnetic Resonance Spectroscopy 3Radiotherapy 2Radiation 2Carmustine 2Carboplatin 2pazopanib 1gallium Ga 68 dotatate 1ficlatuzumab 1cabazitaxel 1Triiodothyronine 1TIC10 compound 1Sunitinib 1Sorafenib 1Procarbazine 1O(6)-benzylguanine 1Nivolumab 1Methimazole 1Magnetic Resonance Imaging 1Lomustine 1Isotretinoin 1Irinotecan 1Gadolinium DTPA 1Filgrastim 1Biopsy 1Axitinib 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Gliosarcoma × cabazitaxel × Clear all
NCT01740570 2018-01-19

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡